1
|
Almiñana-Pastor PJ, Alpiste-Illueca FM, Micó-Martinez P, García-Giménez JL, García-López E, López-Roldán A. MicroRNAs in Gingival Crevicular Fluid: An Observational Case-Control Study of Differential Expression in Periodontitis. Noncoding RNA 2023; 9:73. [PMID: 37987369 PMCID: PMC10660715 DOI: 10.3390/ncrna9060073] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 11/01/2023] [Accepted: 11/16/2023] [Indexed: 11/22/2023] Open
Abstract
OBJECTIVES microRNAs (miRNAs) present in the gingival crevicular fluid (GCF) of patients with chronic periodontitis may serve as biomarkers of periodontal disease. The aim of this study was to perform a miRNA-sequencing study of all miRNAs present in GCF, comparing miRNA expression level profiles between advanced chronic periodontitis (CP) patients and healthy subjects (HS). MATERIALS AND METHODS GCF samples were collected from the single-rooted teeth of patients with severe CP (n = 11) and of HS (n = 12). miRNAs were isolated from GCF using an miRNeasy Serum/Plasma kit(Qiagen GmbH, Hilden, Germany). Reverse transcription polymerase chain reaction (qRT-PCR) was used to determine the expression levels of miRNA candidates involved in periodontal pathogenesis. RESULTS Of all the sequenced miRNAs, miR-199, miR-146a, miR-30a, and miR-338 were identified as best representing the CP patient samples. The validation study identified miR-199 as the most powerful biomarker used to define periodontitis. CONCLUSIONS Upon sequencing all known miRNAs in GCF for the first time, we uncovered several potential biomarkers to define periodontitis. Identifying miRNAS in the GCF using high-throughput approaches will clarify the role of these molecules in periodontitis and provide biomarkers with potential applications.
Collapse
Affiliation(s)
- Pedro J. Almiñana-Pastor
- Department of Stomatology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain; (P.J.A.-P.); (F.M.A.-I.); (P.M.-M.); (A.L.-R.)
| | - Francisco M. Alpiste-Illueca
- Department of Stomatology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain; (P.J.A.-P.); (F.M.A.-I.); (P.M.-M.); (A.L.-R.)
| | - Pablo Micó-Martinez
- Department of Stomatology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain; (P.J.A.-P.); (F.M.A.-I.); (P.M.-M.); (A.L.-R.)
| | - Jose Luis García-Giménez
- Biomedical Research Institute INCLIVA, Consortium Center for Biomedical Network Research on Rare Diseases, CIBERER-ISCIII, 46010 Valencia, Spain
- Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain;
| | - Eva García-López
- Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain;
| | - Andrés López-Roldán
- Department of Stomatology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain; (P.J.A.-P.); (F.M.A.-I.); (P.M.-M.); (A.L.-R.)
| |
Collapse
|
2
|
Sánchez-Sendra B, García-Giménez JL, González-Muñoz JF, Navarro L, Murgui A, Terrádez L, Pinazo I, Martin JM, Monteagudo C. Circulating miRNA expression analysis reveals new potential biomarkers for human cutaneous melanoma staging. J Eur Acad Dermatol Venereol 2020; 34:e126-e129. [PMID: 31710393 DOI: 10.1111/jdv.16060] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- B Sánchez-Sendra
- Department of Pathology, University of Valencia, Valencia, Spain
- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - J L García-Giménez
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain
- Department of Physiology, University of Valencia, Valencia, Spain
| | | | - L Navarro
- Consortium Hospital General Universitario de Valencia, Valencia, Spain
| | - A Murgui
- Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain
| | - L Terrádez
- Department of Pathology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - I Pinazo
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - J M Martin
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - C Monteagudo
- Department of Pathology, University of Valencia, Valencia, Spain
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Pathology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| |
Collapse
|
3
|
Baquero JM, Benítez-Buelga C, Fernández V, Urioste M, García-Giménez JL, Perona R, Benítez J, Osorio A. A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers. Mol Oncol 2019; 13:1110-1120. [PMID: 30747491 PMCID: PMC6487686 DOI: 10.1002/1878-0261.12470] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 02/05/2019] [Accepted: 02/05/2019] [Indexed: 12/11/2022] Open
Abstract
Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes involved in the base excision repair (BER) pathway can modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG) might decrease ovarian cancer risk in BRCA2 mutation carriers. In the present study, we validated this finding in a larger series of familial breast and ovarian cancer patients to gain insights into how this UNG variant exerts its protective effect. We found that rs34259 is associated with significant UNG downregulation and with lower levels of DNA damage at telomeres. In addition, we found that this SNP is associated with significantly lower oxidative stress susceptibility and lower uracil accumulation at telomeres in BRCA2 mutation carriers. Our findings help to explain the association of this variant with a lower cancer risk in BRCA2 mutation carriers and highlight the importance of genetic changes in BER pathway genes as modifiers of cancer susceptibility for BRCA1 and BRCA2 mutation carriers.
Collapse
Affiliation(s)
- Juan Miguel Baquero
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Carlos Benítez-Buelga
- Helleday Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
| | - Victoria Fernández
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Miguel Urioste
- Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.,Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Jose Luis García-Giménez
- Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.,Department of Physiology, Faculty of Medicine and Dentistry, Universitat de Valencia, Mixed Unit CIPF-INCLIVA, Spain
| | - Rosario Perona
- Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.,Biomedical Research Institute Alberto Sols (CSIC-UAM), Madrid, Spain
| | -
- Consortium of Investigators of Modifiers of BRCA1/2
| | - Javier Benítez
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.,Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Ana Osorio
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,Spanish Network on Rare Diseases (CIBERER), Madrid, Spain
| |
Collapse
|
4
|
García-Giménez JL, Romá-Mateo C, Carbonell N, Palacios L, Peiró-Chova L, García-López E, García-Simón M, Lahuerta R, Gimenez-Garzó C, Berenguer-Pascual E, Mora MI, Valero ML, Alpízar A, Corrales FJ, Blanquer J, Pallardó FV. A new mass spectrometry-based method for the quantification of histones in plasma from septic shock patients. Sci Rep 2017; 7:10643. [PMID: 28878320 PMCID: PMC5587716 DOI: 10.1038/s41598-017-10830-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Accepted: 08/16/2017] [Indexed: 01/21/2023] Open
Abstract
The aim of this study was to develop a novel method to detect circulating histones H3 and H2B in plasma based on multiple reaction monitoring targeted mass spectrometry and a multiple reaction monitoring approach (MRM-MS) for its clinical application in critical bacteriaemic septic shock patients. Plasma samples from 17 septic shock patients with confirmed bacteraemia and 10 healthy controls were analysed by an MRM-MS method, which specifically detects presence of histones H3 and H2B. By an internal standard, it was possible to quantify the concentration of circulating histones in plasma, which were significantly higher in patients, and thus confirmed their potential as biomarkers for diagnosing septic shock. After comparing surviving patients and non-survivors, a correlation was found between higher levels of circulating histones and unfavourable outcome. Indeed, histone H3 proved a more efficient and sensitive biomarker for septic shock prognosis. In conclusion, these findings suggest the accuracy of the MRM-MS technique and stable isotope labelled peptides to detect and quantify circulating plasma histones H2B and H3. This method may be used for early septic shock diagnoses and for the prognosis of fatal outcomes.
Collapse
Affiliation(s)
- J L García-Giménez
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain. .,Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain. .,INCLIVA Biomedical Research Institute, Valencia, Spain. .,Epigenetics Research Platform, CIBERER/UV, Valencia, Spain.
| | - C Romá-Mateo
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain.,Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.,INCLIVA Biomedical Research Institute, Valencia, Spain.,Epigenetics Research Platform, CIBERER/UV, Valencia, Spain.,Faculty of Biomedical and Health Sciences, Universidad Europea de Valencia, Valencia, Spain
| | - N Carbonell
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Intensive Care Unit, Clinical University Hospital of Valencia, Valencia, Spain
| | - L Palacios
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Intensive Care Unit, Clinical University Hospital of Valencia, Valencia, Spain
| | - L Peiró-Chova
- INCLIVA Biomedical Research Institute, Valencia, Spain.,INCLIVA Biobank, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - E García-López
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.,INCLIVA Biomedical Research Institute, Valencia, Spain
| | - M García-Simón
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Intensive Care Unit, Clinical University Hospital of Valencia, Valencia, Spain
| | - R Lahuerta
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Intensive Care Unit, Clinical University Hospital of Valencia, Valencia, Spain
| | - C Gimenez-Garzó
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.,INCLIVA Biomedical Research Institute, Valencia, Spain
| | - E Berenguer-Pascual
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.,Epigenetics Research Platform, CIBERER/UV, Valencia, Spain
| | - M I Mora
- Department of Hepatology, Proteomics laboratory, CIMA, University of Navarra; Ciberhed; Idisna; PRB2, ProteoRed-ISCIII, Pamplona, Spain
| | - M L Valero
- Central Service for Experimental Research (SCSIE), University of Valencia, Burjassot, Spain
| | - A Alpízar
- Proteomics Unit, Centro Nacional de Biotecnología (CSIC); PRB2, ProteoRed-ISCIII, Madrid, Spain
| | - F J Corrales
- Proteomics Unit, Centro Nacional de Biotecnología (CSIC); PRB2, ProteoRed-ISCIII, Madrid, Spain
| | - J Blanquer
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Intensive Care Unit, Clinical University Hospital of Valencia, Valencia, Spain
| | - F V Pallardó
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain. .,Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain. .,INCLIVA Biomedical Research Institute, Valencia, Spain. .,Epigenetics Research Platform, CIBERER/UV, Valencia, Spain.
| |
Collapse
|
5
|
Zapatero-Solana E, García-Giménez JL, Guerrero-Aspizua S, García M, Toll A, Baselga E, Durán-Moreno M, Markovic J, García-Verdugo JM, Conti CJ, Has C, Larcher F, Pallardó FV, Del Rio M. Oxidative stress and mitochondrial dysfunction in Kindler syndrome. Orphanet J Rare Dis 2014; 9:211. [PMID: 25528446 PMCID: PMC4302591 DOI: 10.1186/s13023-014-0211-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Accepted: 12/10/2014] [Indexed: 11/29/2022] Open
Abstract
Background Kindler Syndrome (KS) is an autosomal recessive skin disorder characterized by skin blistering, photosensitivity, premature aging, and propensity to skin cancer. In spite of the knowledge underlying cause of this disease involving mutations of FERMT1 (fermitin family member 1), and efforts to characterize genotype-phenotype correlations, the clinical variability of this genodermatosis is still poorly understood. In addition, several pathognomonic features of KS, not related to skin fragility such as aging, inflammation and cancer predisposition have been strongly associated with oxidative stress. Alterations of the cellular redox status have not been previously studied in KS. Here we explored the role of oxidative stress in the pathogenesis of this rare cutaneous disease. Methods Patient-derived keratinocytes and their respective controls were cultured and classified according to their different mutations by PCR and western blot, the oxidative stress biomarkers were analyzed by spectrophotometry and qPCR and additionally redox biosensors experiments were also performed. The mitochondrial structure and functionality were analyzed by confocal microscopy and electron microscopy. Results Patient-derived keratinocytes showed altered levels of several oxidative stress biomarkers including MDA (malondialdehyde), GSSG/GSH ratio (oxidized and reduced glutathione) and GCL (gamma-glutamyl cysteine ligase) subunits. Electron microscopy analysis of both, KS skin biopsies and keratinocytes showed marked morphological mitochondrial abnormalities. Consistently, confocal microscopy studies of mitochondrial fluorescent probes confirmed the mitochondrial derangement. Imbalance of oxidative stress biomarkers together with abnormalities in the mitochondrial network and function are consistent with a pro-oxidant state. Conclusions This is the first study to describe mitochondrial dysfunction and oxidative stress involvement in KS. Electronic supplementary material The online version of this article (doi:10.1186/s13023-014-0211-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elisabeth Zapatero-Solana
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Regenerative Medicine Unit. Departament of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. .,Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| | - Jose Luis García-Giménez
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain. .,Fundación Investigación Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, Valencia, Spain.
| | - Sara Guerrero-Aspizua
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Regenerative Medicine Unit. Departament of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. .,Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| | - Marta García
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Regenerative Medicine Unit. Departament of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. .,Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| | - Agustí Toll
- Servei de Dermatologia, Hospital del Mar, Parc de Salut Mar, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.
| | - Eulalia Baselga
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | - Maria Durán-Moreno
- Laboratorio de Neurobiología Comparada, Instituto Cavanilles, Universidad de Valencia, CIBERNED, Valencia, Spain.
| | - Jelena Markovic
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain. .,Fundación Investigación Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, Valencia, Spain.
| | - Jose Manuel García-Verdugo
- Laboratorio de Neurobiología Comparada, Instituto Cavanilles, Universidad de Valencia, CIBERNED, Valencia, Spain.
| | - Claudio J Conti
- Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| | - Cristina Has
- Department of Dermatology, Medical Centre-University of Freiburg, Freiburg, Germany.
| | - Fernando Larcher
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Regenerative Medicine Unit. Departament of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. .,Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| | - Federico V Pallardó
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain. .,Fundación Investigación Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, Valencia, Spain.
| | - Marcela Del Rio
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Valencia, Spain. .,Regenerative Medicine Unit. Departament of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. .,Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain. .,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
| |
Collapse
|
6
|
Manguan-Garcia C, Pintado-Berninches L, Carrillo J, Machado-Pinilla R, Sastre L, Pérez-Quilis C, Esmoris I, Gimeno A, García-Giménez JL, Pallardó FV, Perona R. Expression of the genetic suppressor element 24.2 (GSE24.2) decreases DNA damage and oxidative stress in X-linked dyskeratosis congenita cells. PLoS One 2014; 9:e101424. [PMID: 24987982 PMCID: PMC4079255 DOI: 10.1371/journal.pone.0101424] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Accepted: 06/06/2014] [Indexed: 01/10/2023] Open
Abstract
The predominant X-linked form of Dyskeratosis congenita results from mutations in DKC1, which encodes dyskerin, a protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis congenita (X-DC) patient cells. Here we have found that an increased basal and induced DNA damage response occurred in X-DC cells in comparison with normal cells. DNA damage that is also localized in telomeres results in increased heterochromatin formation and senescence. Expression of a cDNA coding for GSE24.2 rescues both global and telomeric DNA damage. Furthermore, transfection of bacterial purified or a chemically synthesized GSE24.2 peptide is able to rescue basal DNA damage in X-DC cells. We have also observed an increase in oxidative stress in X-DC cells and expression of GSE24.2 was able to diminish it. Altogether our data indicated that supplying GSE24.2, either from a cDNA vector or as a peptide reduces the pathogenic effects of Dkc1 mutations and suggests a novel therapeutic approach.
Collapse
Affiliation(s)
- Cristina Manguan-Garcia
- Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
- CIBER de Enfermedades Raras, Valencia, Spain
| | | | - Jaime Carrillo
- Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
| | - Rosario Machado-Pinilla
- Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
- CIBER de Enfermedades Raras, Valencia, Spain
| | - Leandro Sastre
- Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
- CIBER de Enfermedades Raras, Valencia, Spain
| | - Carme Pérez-Quilis
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Isabel Esmoris
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Amparo Gimeno
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Jose Luis García-Giménez
- CIBER de Enfermedades Raras, Valencia, Spain
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Federico V. Pallardó
- CIBER de Enfermedades Raras, Valencia, Spain
- Biomedical Research Institute INCLIVA, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Rosario Perona
- Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
- CIBER de Enfermedades Raras, Valencia, Spain
- * E-mail:
| |
Collapse
|
7
|
García-Giménez JL, Sanchis-Gomar F, Lippi G, Mena S, Ivars D, Gomez-Cabrera MC, Viña J, Pallardó FV. Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin Chim Acta 2012; 413:1576-82. [PMID: 22664147 DOI: 10.1016/j.cca.2012.05.021] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Revised: 05/23/2012] [Accepted: 05/25/2012] [Indexed: 02/08/2023]
Abstract
Epigenetics comprises the study of chemical modifications in the DNA and histones that regulates the gene expression or cellular phenotype. However, during the last decade this term has evolved after the elucidation of different mechanisms (microRNAs and nuclear organization of the chromosomes) involved in regulating gene expression. Epigenetics and the new designed technologies capable to analyze epigenetic changes (e.g., methylated DNA, miRNAs expression, post-translational modifications on histones among others) have disclosed an appealing scenario that will offer for the biomedical sciences new biomarkers for the study of neurodegenerative diseases, multifactorial complex diseases, rare diseases and cancer. Moreover, new technologies adapted for epigenetic studies will offer promising applications that in the next years will be common technologies in clinical laboratories. In this review we discuss epigenetic modifications used as possible biomarkers in several diseases. We also present the potential of methodologies to purify histones, and high throughput technologies as candidates to be set in clinical laboratories for their high potential analyzing epigenetic processes.
Collapse
Affiliation(s)
- J L García-Giménez
- CIBERER, The Biomedical Network Research Centre on Rare Diseases. Valencia, Spain.
| | | | | | | | | | | | | | | |
Collapse
|